150.79 -0.59 (-0.39%) | 10-04 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 181.74 | 1-year : | 186.13 |
Resists | First : | 155.6 | Second : | 159.36 |
Pivot price | 154.07 | |||
Supports | First : | 149.52 | Second : | 124.4 |
MAs | MA(5) : | 153.39 | MA(20) : | 154.04 |
MA(100) : | 146.56 | MA(250) : | 137.52 | |
MACD | MACD : | 0.1 | Signal : | 0.6 |
%K %D | K(14,3) : | 22.4 | D(3) : | 41.5 |
RSI | RSI(14): 41.6 | |||
52-week | High : | 159.36 | Low : | 120.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DGX ] has closed below the lower bollinger band by 6.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 152.61 - 153.57 | 153.57 - 154.24 |
Low: | 148.13 - 149.33 | 149.33 - 150.18 |
Close: | 149.22 - 150.97 | 150.97 - 152.21 |
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Mon, 07 Oct 2024
Brokers Set Expectations for Quest Diagnostics Incorporated's Q1 2025 Earnings (NYSE:DGX) - MarketBeat
Sat, 05 Oct 2024
Do Fundamentals Have Any Role To Play In Driving Quest Diagnostics Incorporated's (NYSE:DGX) Stock Up Recently? - Simply Wall St
Fri, 04 Oct 2024
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Fri, 04 Oct 2024
Quest Diagnostics' Quarterly Earnings Preview: What You Need to Know - Nasdaq
Fri, 04 Oct 2024
Mackenzie Financial Corp Lowers Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Wed, 02 Oct 2024
Is Now An Opportune Moment To Examine Quest Diagnostics Incorporated (NYSE:DGX)? - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Diagnostics & Research
|
|
Shares Out | 111 (M) |
Shares Float | 110 (M) |
Held by Insiders | 0.4 (%) |
Held by Institutions | 91.6 (%) |
Shares Short | 2,420 (K) |
Shares Short P.Month | 2,790 (K) |
EPS | 7.4 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 59.61 |
Profit Margin | 8.9 % |
Operating Margin | 15.5 % |
Return on Assets (ttm) | 6.1 % |
Return on Equity (ttm) | 13.5 % |
Qtrly Rev. Growth | 2.5 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 83.99 |
EBITDA (p.s.) | 16.07 |
Qtrly Earnings Growth | -1 % |
Operating Cash Flow | 1,250 (M) |
Levered Free Cash Flow | 788 (M) |
PE Ratio | 20.34 |
PEG Ratio | 2.7 |
Price to Book value | 2.52 |
Price to Sales | 1.79 |
Price to Cash Flow | 13.42 |
Dividend | 0.75 |
Forward Dividend | 0 |
Dividend Yield | 0.4% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |